Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

NSC 3051

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryFifty-four evaluable patients with SCLC previously treated with chemotherapy received either N-methylformamide or… Expand
  • table 1
Is this relevant?
2004
2004
SummaryTwenty patients with advanced measurable, squamous carcinoma of the cervix were treated with 25 courses of N-MF at doses… Expand
  • table 2
  • table 1
Is this relevant?
1990
1990
Twenty patients with advanced measurable, squamous carcinoma of the cervix were treated with 25 courses of N-MF at doses ranging… Expand
Is this relevant?
1990
1990
SummaryForty-four patients with advanced, measurable, epithelial carcinoma of the ovary were treated with 97 courses of N… Expand
Is this relevant?
1986
1986
Abstract N-Methylformamide (NMF, NSC 3051) is an antineoplastic agent in mice[1,2]. In clinical trials in which the potential of… Expand
Is this relevant?
1985
1985
N-Methylformamide (NMF) was found to be non-toxic to the bone marrow as reflected in the absence of leukopenia in mice, even when… Expand
Is this relevant?
1985
1985
N-methylformamide (NMF) is a polar-planar solvent with both cytotoxic and differentiating activity in preclinical models; it also… Expand
Is this relevant?
1983
1983
Experiments were conducted to test the hypothesis that N-hydroxymethylformamide (HMF) is the active metabolite of the antitumour… Expand
Is this relevant?